BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, Portmann B, Alexander GJ, Williams R. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14:104-111. [PMID: 1737910 DOI: 10.1016/0168-8278(92)90138-f] [Cited by in Crossref: 310] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Ishigami M, Ogura Y, Hirooka Y, Goto H. Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2015; 21(36): 10290-10298 [PMID: 26420956 DOI: 10.3748/wjg.v21.i36.10290] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dehghani SM, Taghavi SA, Geramizadeh B, Nikeghbalian S, Derakhshan N, Malekpour A, Malek-Hosseini SA. Hepatitis B recurrence after liver transplantation: a single center experiences and review the literature. Hepat Mon. 2013;13:e6609. [PMID: 23483668 DOI: 10.5812/hepatmon.6609] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
3 Ma K, Yu Y, Bu XM, Li YJ, Dai XW, Wang L, Dai Y, Zhao HY, Yang XH. Prevention of grafted liver from reperfusive injury. World J Gastroenterol 2001; 7(4): 572-574 [PMID: 11819833 DOI: 10.3748/wjg.v7.i4.572] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
4 Vasudevan A, Ardalan ZS, Ahmed N, Apostolov R, Gow PJ, Testro AG, Gane EJ, Angus PW. Long-term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation. JGH Open 2018;2:288-94. [PMID: 30619939 DOI: 10.1002/jgh3.12086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Shinzato T, Kubo T, Shimizu T, Nanmoku K, Yagisawa T. Fibrosing cholestatic hepatitis in a kidney transplant recipient with hepatitis C virus. CEN Case Rep 2019;8:101-5. [PMID: 30604247 DOI: 10.1007/s13730-018-0374-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 He XS, Huang JF, Chen GH, Fu Q, Zhu XF, Lu MQ, Wang GD, Guan XD. Orthotopic liver transplantation for fulminant hepatitis B. World J Gastroenterol 2000; 6(3): 398-399 [PMID: 11819607 DOI: 10.3748/wjg.v6.i3.398] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
7 Naoumov NV, Eddleston AL. Host immune response and variations in the virus genome: pathogenesis of liver damage caused by hepatitis B virus. Gut 1994;35:1013-7. [PMID: 7926896 DOI: 10.1136/gut.35.8.1013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 0.8] [Reference Citation Analysis]
8 Ryder SD, Williams R. Liver disease. Postgrad Med J 1994;70:162-84. [PMID: 8183748 DOI: 10.1136/pgmj.70.821.162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
9 Khemichian S, Hsieh MJ, Zhang SR, Limurti J, Kim J, Fong TL. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation. Dig Dis Sci 2015;60:2807-12. [PMID: 25939541 DOI: 10.1007/s10620-015-3671-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
10 Yilmaz S, Kirimlioglu V, Kirimlioglu H, Coban S, Kayaalp C, Yilmaz M, Karakoc Y, Alan S. Effects of nucleoside analogues on liver regeneration 70% partially hepatectomized rats. Transplant Proc 2006;38:568-70. [PMID: 16549177 DOI: 10.1016/j.transproceed.2006.01.021] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Al-hamoudi W, Elsiesy H, Bendahmash A, Al-masri N, Ali S, Allam N, Al Sofayan M, Al Bahili H, Al Sebayel M, Broering D, Saab S, Abaalkhail F. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. World J Gastroenterol 2015; 21(26): 8140-8147 [PMID: 26185387 DOI: 10.3748/wjg.v21.i26.8140] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
12 Buti M, Castells L. Prevention and treatment of hepatitis B virus recurrence after liver transplantation: . Current Opinion in Organ Transplantation 2006;11:589-93. [DOI: 10.1097/mot.0b013e3280102b22] [Reference Citation Analysis]
13 Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20): 2468-2475 [PMID: 20503446 DOI: 10.3748/wjg.v16.i20.2468] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
14 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Jo HS, Khan JF, Han JH, Yu YD, Kim DS. Efficacy and Safety of Hepatitis B Virus Vaccination Following Hepatitis B Immunoglobulin Withdrawal After Liver Transplantation. Transplant Proc 2021:S0041-1345(21)00736-3. [PMID: 34740450 DOI: 10.1016/j.transproceed.2021.09.038] [Reference Citation Analysis]
16 Jothimani D, Venugopal R, Vij M, Rela M. Post liver transplant recurrent and de novo viral infections. Best Pract Res Clin Gastroenterol. 2020;46-47:101689. [PMID: 33158469 DOI: 10.1016/j.bpg.2020.101689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Walsh K, Alexander GJ. Update on chronic viral hepatitis. Postgrad Med J 2001;77:498-505. [PMID: 11470928 DOI: 10.1136/pmj.77.910.498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
18 Wang P, Tam N, Wang H, Zheng H, Chen P, Wu L, He X. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One. 2014;9:e104480. [PMID: 25102072 DOI: 10.1371/journal.pone.0104480] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
19 Aldersley MA, O'Grady JG. Hepatic disorders. Features and appropriate management. Drugs 1995;49:83-102. [PMID: 7705218 DOI: 10.2165/00003495-199549010-00007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
20 Starkey JL, Chiari EF, Isom HC. Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro. J Gen Virol. 2009;90:115-126. [PMID: 19088280 DOI: 10.1099/vir.0.004408-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
21 Xi ZF, Xia Q. Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol 2015; 21(3): 829-835 [PMID: 25624716 DOI: 10.3748/wjg.v21.i3.829] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
22 Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs. 1999;58:101-141. [PMID: 10439933 DOI: 10.2165/00003495-199958010-00015] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 4.2] [Reference Citation Analysis]
23 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
24 Hori T, Onishi Y, Kamei H, Kurata N, Ishigami M, Ishizu Y, Ogura Y. Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Ann Gastroenterol 2016;29:454-9. [PMID: 27708510 DOI: 10.20524/aog.2016.0069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, Ryan TS, Kuhns M, McNamara A, Caldwell SH. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg. 1998;227:841-850. [PMID: 9637547 DOI: 10.1097/00000658-199806000-00007] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 5.0] [Reference Citation Analysis]
26 Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, Kunder G, Chen PW, Farmer DG, Yersiz H. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg. 2002;235:611-619; discussion 619-620. [PMID: 11981206 DOI: 10.1097/00000658-200205000-00002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis]
27 Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoka D, Utsumi M. Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol. 2013;48:1373-1383. [PMID: 23435670 DOI: 10.1007/s00535-013-0763-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
28 Gopal PB, Kapoor D, Raya R, Subrahmanyam M, Juneja D, Sukanya B. Critical care issues in adult liver transplantation. Indian J Crit Care Med 2009;13:113-9. [PMID: 20040807 DOI: 10.4103/0972-5229.58535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
29 Ajayi T, Luu H, Saberi B, Hamilton JP, Konduk BT, Özşeker B, Al Khalloufi K, Pustavoitau A, Philosophe B, Cameron AM, Gürakar A. Role of nucleoside/nucleotide analogues and low-dose hepatitis B immune globülin in prophylaxis of hepatitis B recurrence among cadaveric liver transplant recipients. Turk J Gastroenterol 2018;29:61-6. [PMID: 29391309 DOI: 10.5152/tjg.2018.17595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Yasunaka T, Takaki A, Yagi T, Iwasaki Y, Sadamori H, Koike K, Hirohata S, Tatsukawa M, Kawai D, Shiraha H. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int. 2011;5:918-926. [PMID: 21484119 DOI: 10.1007/s12072-011-9265-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
31 Tchervenkov JI, Tector AJ, Barkun JS, Sherker A, Forbes CD, Elias N, Cantarovich M, Cleland P, Metrakos P, Meakins JL. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 1997;226:356-65; discussion 365-8. [PMID: 9339942 DOI: 10.1097/00000658-199709000-00015] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.4] [Reference Citation Analysis]
32 Metin O, Şimşek C, Gürakar A. Update on liver transplantation-newer aspects. Turk J Med Sci 2020;50:1642-50. [PMID: 32222125 DOI: 10.3906/sag-2002-17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Wang K, Zhu ZJ, Zheng H, Deng YL, Pan C, Sun LY, Shen ZY. Protective hepatitis B surface antibodies in blood and ascites fluid in the early stage after liver transplantation for hepatitis B diseases. Hepatol Res 2012;42:280-7. [PMID: 22176205 DOI: 10.1111/j.1872-034X.2011.00926.x] [Reference Citation Analysis]
34 Fung J. Management of chronic hepatitis B before and after liver transplantation. World J Hepatol 2015; 7(10): 1421-1426 [PMID: 26052387 DOI: 10.4254/wjh.v7.i10.1421] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
35 Lew YY, Michalak TI. In vitro and in vivo infectivity and pathogenicity of the lymphoid cell-derived woodchuck hepatitis virus. J Virol. 2001;75:1770-1782. [PMID: 11160675 DOI: 10.1128/jvi.75.4.1770-1782.2001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
36 Schreibman IR, Schiff ER. Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 2006;5:8. [PMID: 16600049 DOI: 10.1186/1476-0711-5-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
37 Vierling JM. Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci 2005;2:41-9. [PMID: 15968339 DOI: 10.7150/ijms.2.41] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
38 Mitchell O, Cosar AM, Malik MU, Gurakar A. Late liver function test abnormalities post-adult liver transplantation: a review of the etiology, investigation, and management. Hepatol Int 2016;10:106-14. [PMID: 26603541 DOI: 10.1007/s12072-015-9685-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]